Faramand, R., Jain, M., Staedtke, V., Kotani, H., Bai, R., Reid, K., . . . Davila, M. L. (2020). Tumor Microenvironment composition and severe cytokine release syndrome (CRS) Influence Toxicity in Patients with Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res.
Citação norma ChicagoFaramand, Rawan, et al. "Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients With Large B Cell Lymphoma Treated With Axicabtagene Ciloleucel." Clin Cancer Res 2020.
MLA citiranjeFaramand, Rawan, et al. "Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients With Large B Cell Lymphoma Treated With Axicabtagene Ciloleucel." Clin Cancer Res 2020.